Photo from academic.microsoft.com
The MENTOR trial reported that rituximab is superior to ciclosporin for remission of nephrotic syndrome in patients with membranous nephropathy. Rituximab is better tolerated than other treatments but, as up… Click to show full abstract
The MENTOR trial reported that rituximab is superior to ciclosporin for remission of nephrotic syndrome in patients with membranous nephropathy. Rituximab is better tolerated than other treatments but, as up to 40% of patients did not respond to rituximab, alternative immunosuppressive therapies may still be required for a substantial minority of patients.
Keywords:
mentor;
mentor heralds;
heralds new;
membranous nephropathy;
new era;
era therapy
Journal Title: Nature Reviews Nephrology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Nature Reviews Nephrology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!